ERX-208 / EtiraRx - LARVOL DELTA

LIPA inhibition enhances the therapeutic efficacy of DNA-damaging agents in ovarian cancer through induction of ER stress and enhancing DNA damage (AACR 2026) - "Combination treatments with paclitaxel or cisplatin further amplified these effects, significantly reducing cell viability across OCa cell lines compared to monotherapy. Our findings demonstrate that combining ERX-208 with DNA-damaging agents significantly enhances therapeutic efficacy, highlighting the potential of ERX-208-based combination therapy for treating OCa."

Clinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Preclinical evaluation of ERX-208, a potent inducer of ER stress for the treatment of ovarian cancer (AACR 2024) - "Collectively, our findings underscore the preclinical promise of ERX-208 as a potential therapeutic agent for treating OCa. Conflict: The patents surrounding ERX-208 are licensed to EtiraRx."

Preclinical • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • HSPA5

Optimization of the LIPA targeting agent for the treatment of ovarian cancer (AACR 2025) - "Recent findings indicate that elevated basal levels of endoplasmic reticulum stress (ERS) in OCa represent a significant vulnerability and identified LIPA as a novel target for inducing ERS in cancer cells with the oligobenzamide ERX-41. These findings suggest that ERX-208 is a promising candidate as a therapeutic agent in OCa treatment. Since a related analog of ERX-208, ERX-315 is in clinical trials, these data strongly support the evaluation of ERX-208 in patients with OCa."

Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • HSPA5

Therapeutic optimization of LIPA targeting to induce endoplasmic reticulum stress and cell death in ovarian cancer. (PubMed, Oncogene) - "We have previously shown that the tris-benzamide ERX-41 can induce ERS and cancer cell death in OCa by targeting LIPA. Immunohistochemical analysis of treated tumors demonstrated changes in expression of proliferative marker (ki67, decreased) and the ERS marker (GRP78, increased). These findings support the clinical advancement of ERX-208 for the treatment of patients with OCa."

Journal • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • HSPA5

Preclinical Data on ERX-208 and ERX-315 to Be Presented at AACR 2025 (ABN Newswire) - "Etira announced three presentations at the AACR Annual Meeting 2025 featuring new preclinical data on its LIPA-targeting compounds ERX-208 and ERX-315....Three presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025 showcase the ongoing development of Etira's platform that targets lysosomal acid lipase A (LIPA) to induce endoplasmic reticulum (ER) stress and cell death in cancer."

Preclinical • Hepatocellular Cancer • Ovarian Cancer

ERX-208 as a novel therapeutic for treating ovarian cancer by enhancing endoplasmic reticulum stress (AACR 2023) - "Collectively, our results demonstrated the utility of ERX-208 and will establish a novel therapeutic paradigm in OCa that overcomes tumor heterogeneity by targeting LIPA and enhancing ERS leading to apoptosis."

Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor • HSPA5 • XBP1